Pediatric Outcomes in Transplant: PersOnaliSing Immunosuppression To ImproVe Efficacy (POSITIVE Study): The Collaboration and Design of a National Transplant Precision Medicine Program

Tanya Papaz, Upton Allen, Tom Blydt-Hansen, Patricia E Birk, Sandar Min, Lorraine Hamiwka, Veronique Phan, Tal Schechter, Donna A Wall, Simon Urschel, Bethany J Foster, Seema Mital, Tanya Papaz, Upton Allen, Tom Blydt-Hansen, Patricia E Birk, Sandar Min, Lorraine Hamiwka, Veronique Phan, Tal Schechter, Donna A Wall, Simon Urschel, Bethany J Foster, Seema Mital

Abstract

Background: Despite age-related differences in biology, physiology, and behavior, transplant immunosuppression is not tailored by age. This likely contributes to high graft failure and posttransplant complications. We present the aims, design, and methods of the Pediatric Outcomes in Transplant: PersOnaliSing Immunosuppression To ImproVe Efficacy Study aimed at personalizing posttransplant immunosuppression in children and young adults.

Methods: In this prospective observational cohort study, we recruited pediatric and young adult solid organ transplant, pediatric allogeneic hematopoietic stem cell transplant recipients, and matched living and deceased organ donors from 14 transplant centers across Canada. Clinical data, questionnaires, biospecimens, and pharmacy records were collected at serial time points: (1) to identify genetic and host immune factors that influence immunosuppression dose requirements across different ages and transplant types, (2) to identify viral-host interactions that increase susceptibility to Epstein-Barr virus infection, and (3) to define care processes and structures associated with medication adherence in adolescents and young adults.

Results: From 2015 to 2018, 1662 new and prevalent transplant recipients were screened, 1166 were recruited for the various aims, including 370 liver, 445 kidney, 277 heart, 19 lung, 19 multiple, and 36 hematopoietic stem cell transplant transplants. Twelve percent were younger than 2 years, 30% were 2 to 10 years, 42% were 10 to 18 years, and 16% were 18 to 24 years at enrollment. Nine hundred thirty-one consented to participation in aims 1 and 2 (90% consent rate), 287 to aim 3 (82% consent rate). Biospecimens collected included 898 for DNA, 276 for immunoassays, and 717 for biomarker studies. Seventy percent participants have completed follow-up; 30% are pending study completion.

Conclusions: The design of this national multicenter cross-organ network helped maximize recruitment of a large patient cohort for studying age and organ-related differences in immunosuppression needs that would not otherwise be feasible. Leveraging the unique clinical, biological, environmental, and behavioral characteristics of this cohort will help develop precision medicine strategies for individualizing posttransplant immunosuppression.

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Clinical and research disciplines involved in project aims.
FIGURE 2
FIGURE 2
POSITIVE Study participating sites (pediatric solid organ transplant center only ☆, pediatric solid organ and hematopoietic transplant center ★, adult solid organ transplant center ▲).
FIGURE 3
FIGURE 3
Screening and enrollment summary for POSITIVE study aims.

References

    1. Canadian Institutes for Health Information (CIHI). Canadian organ replacement register (CORR). Available at: . Published 2017.
    1. D'Souza AFC. Current uses and outcomes of hematopoietic cell transplantation (hct): CIBMTR summary slides. Available at: . Published 2017.
    1. Fan X, Ang A, Pollock-Barziv SM, et al. Donor-specific b-cell tolerance after abo-incompatible infant heart transplantation. Nat Med. 2004;10:1227–1233.
    1. Kirk R, Edwards LB, Kucheryavaya AY, et al. The registry of the international society for heart and lung transplantation: fourteenth pediatric heart transplantation report—2011. J Heart Lung Transplant. 2011;30:1095–1103.
    1. Urschel S, Cremer S, Birnbaum J, et al. Lack of serologic immunity against vaccine-preventable diseases in children after thoracic transplantation. Transpl Int. 2010;23:619–627.
    1. Urschel S, Rieck BD, Birnbaum J, et al. Impaired cellular immune response to diphtheria and tetanus vaccines in children after thoracic transplantation. Pediatr Transplant. 2011;15:272–280.
    1. Pollock-Barziv SM, Finkelstein Y, Manlhiot C, et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transplant. 2010;14:968–975.
    1. Foster BJ, Dahhou M, Zhang X, et al. Association between age and graft failure rates in young kidney transplant recipients. Transplantation. 2011;92:1237–1243.
    1. Berquist RK, Berquist WE, Esquivel CO, et al. Non-adherence to post-transplant care: prevalence, risk factors and outcomes in adolescent liver transplant recipients. Pediatr Transplant. 2008;12:194–200.
    1. Chisholm-Burns MA, Spivey CA, Rehfeld R, et al. Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. Am J Transplant. 2009;9:2497–2504.
    1. Feinstein S, Keich R, Becker-Cohen R, et al. Is noncompliance among adolescent renal transplant recipients inevitable? Pediatrics. 2005;115:969–973.
    1. Hsu DT. Biological and psychological differences in the child and adolescent transplant recipient. Pediatr Transplant. 2005;9:416–421.
    1. Keith DS, Cantarovich M, Paraskevas S, et al. Recipient age and risk of chronic allograft nephropathy in primary deceased donor kidney transplant. Transpl Int. 2006;19:649–656.
    1. Takemoto SK, Pinsky BW, Schnitzler MA, et al. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am J Transplant. 2007;7:2704–2711.
    1. Gijsen V, Mital S, van Schaik RH, et al. Age and cyp3a5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J Heart Lung Transplant. 2011;30:1352–1359.
    1. Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87:721–726.
    1. Clinical trials in organ transplantation in children (CTOT-C). Available at: . Published 2009.
    1. McCarty TP, Baddley JW, Walsh TJ, et al. Phaeohyphomycosis in transplant recipients: results from the transplant associated infection surveillance network (transnet). Med Mycol. 2015;53:440–446.
    1. GiaQuinta S, Michaels MG, McCullers JA, et al. Randomized, double-blind comparison of standard-dose vs. high-dose trivalent inactivated influenza vaccine in pediatric solid organ transplant patients. Pediatr Transplant. 2015;19:219–228.
    1. Hebert MJ, Hartell D, West L. Transdisciplinary tour-de-force: the Canadian national transplant research program. Transplantation. 2016;100:466–470.
    1. International Genetics & Translational Research in Transplantation Network (iGeneTRAiN). Design and implementation of the international genetics and translational research in transplantation network. Transplantation. 2015;99:2401–2412.
    1. Li YR, van Setten J, Verma SS, et al. Concept and design of a genome-wide association genotyping array tailored for transplantation-specific studies. Genome Med. 2015;7:90.
    1. Solez K, Colvin RB, Racusen LC, et al. Banff ’05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’). Am J Transplant. 2007;7:518–526.
    1. Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914–956.
    1. Ormonde DG, de Boer WB, Kierath A, et al. Banff schema for grading liver allograft rejection: utility in clinical practice. Liver Transpl Surg. 1999;5:261–268.
    1. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant. 2007;26:1229–1242.
    1. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. J Am Soc Nephrol. 2009;4:1832–1643.
    1. Kangro HO, Osman HK, Lau YL, et al. Seroprevalence of antibodies to human herpesviruses in England and Hong Kong. J Med Virol. 1994;43:91–96.
    1. Jeong HJ, Ahn YH, Park E, et al. Posttransplantation lymphoproliferative disorder after pediatric solid organ transplantation: experiences of 20 years in a single center. Korean J Pediatr. 2017;60:86–93.
    1. Barton M, Wasfy S, Hebert D, et al. Exploring beyond viral load testing for EBV lymphoproliferation: role of serum il-6 and IgE assays as adjunctive tests. Pediatr Transplant. 2010;14:852–858.
    1. Allen UD, Farkas G, Hebert D, et al. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study. Pediatr Transplant. 2005;9:450–455.
    1. Chang CM, Yu KJ, Mbulaiteye SM, et al. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res. 2009;143:209–221.
    1. Simons LE, Blount RL. Identifying barriers to medication adherence in adolescent transplant recipients. J Pediatr Psychol. 2007;32:831–844.
    1. C.D.A. The spectrum of adherence among hemodialysis patients. J Nephrol Soc Work. 1998;18:53–65.
    1. De Geest S, Sabate E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003;2:323.
    1. Berben L, Dobbels F, Engberg S, et al. An ecological perspective on medication adherence. West J Nurs Res. 2012;34:635–653.
    1. Held PJ, Kahan BD, Hunsicker LG, et al. The impact of HLA mismatches on the survival of first cadaveric kidney transplants. N Engl J Med. 1994;331:765–770.
    1. Pai AL, Rausch J, Tackett A, et al. System for integrated adherence monitoring: real-time non-adherence risk assessment in pediatric kidney transplantation. Pediatr Transplant. 2012;16:329–334.
    1. Shemesh E, Shneider BL, Savitzky JK, et al. Medication adherence in pediatric and adolescent liver transplant recipients. Pediatrics. 2004;113:825–832.
    1. Shemesh E, Annunziato RA, Shneider BL, et al. Improving adherence to medications in pediatric liver transplant recipients. Pediatr Transplant. 2008;12:316–323.
    1. Schafer-Keller P, Steiger J, Bock A, et al. Diagnostic accuracy of measurement methods to assess non-adherence to immunosuppressive drugs in kidney transplant recipients. Am J Transplant. 2008;8:616–626.
    1. Miloh T, Annunziato R, Arnon R, et al. Improved adherence and outcomes for pediatric liver transplant recipients by using text messaging. Pediatrics. 2009;124:e844–e850.
    1. Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cyp3a5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98:19–24.
    1. Min S, Daljevic T, Lee O, et al. Variability in tacrolimus concentrations across pediatric solid organ transplants. Am J Transplant. 2017;17(suppl 3).
    1. Min S, Papaz T, Blydt-Hansen T, et al. Genome-wide association study of tacrolimus dose in pediatric solid organ transplant recipients in the CNTRP positive study. Am J Transplant. 2017;17(suppl 3).
    1. Papaz T, Min S, Lee O, et al. Genome-wide association study assessing risk of rejection in pediatric transplant recipients. Am J Transplant. 2017;17(suppl 3).
    1. Urschel S, Ionescu L, Blydt-Hansen T, et al. Immune phenotyping in a pediatric multicenter transplant study: suitability of a pre-formulated dry antibody panel system. Am J Transplant. 2017;17(suppl 3).
    1. Ionescu L, Blydt-Hansen T, Foster B, et al. The impact of childhood solid organ transplantation on b-cell maturation. Am J Transplant. 2017;17(suppl 3).

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다